StockData

Johnson & Johnson vs Merck

JNJ and MRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JNJ and MRK compare

Johnson & Johnson is the larger company, worth 1.9 times as much as Merck ($671B against $356B).

On earnings, Johnson & Johnson is cheaper: it trades at 42.3× trailing earnings, against 116× for Merck.

Johnson & Johnson grew revenue faster over the last twelve months (7.8% versus 4.6% for Merck).

Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 4.8% at Merck.

Both pay dividends: Johnson & Johnson yields 1.9% and Merck 2.4%.

Johnson & Johnson scores higher on the StockData Score (12 against 9 for Merck), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJNJMRK
Size and price
Market cap$671B$356B
Share price$278.70$144.46
Change, 1 year42.2%55.5%
Change, 5 years75.1%82.5%
Beta (5Y)−0.30−0.14
Employees138K75K
StockData Score
Total score12 (better)9
Valuation score00
Growth score3 (better)0
Performance score4 (better)3
Health score33
Dividend score23 (better)
Valuation
P/E42.3× (better)116×
P/S6.8×5.4× (better)
P/B8.2× (better)8.5×
EV/EBITDA26.0×–
P/FCF32.6×22.2× (better)
PEG2.36 (better)13.70
FCF yield3.1%4.5% (better)
Fair value$150.10$42.50
Margin of safety−85.7% (better)−240%
Growth
Revenue growth (TTM)7.8% (better)4.6%
Revenue growth, 5Y average2.7%9.4% (better)
Net income growth (TTM)−35.9% (better)−80.7%
EPS growth (TTM)−36.4% (better)−80.7%
EPS growth, 5Y average14.9%21.2% (better)
Profitability
Gross margin67.6%73.0% (better)
Net margin16.2% (better)4.8%
FCF margin20.7%24.1% (better)
Return on equity20.0% (better)7.0%
Financial health
Debt / equity0.55 (better)1.29
Net debt / EBITDA1.02–
Current ratio1.021.32 (better)
Altman Z-score5.18 (better)3.71
Piotroski F-score44
Dividends and buybacks
Dividend yield1.9%2.4% (better)
Payout ratio–262%
Years of dividend growth16 (better)15
Dividend growth, 5Y average5.2%5.8% (better)
Buyback yield1.2%1.2% (better)
Shareholder yield3.1%3.5% (better)
Ownership
Held by institutions74.8%80.3%
Held by insiders0.04%0.05%
Insider net buying, 12 months−$154M−$79.3M (better)
Superinvestors holding6 (better)4
Short interest, % of float0.71%1.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.